Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | QPCT | Q16769 | 1/20 | 0.73 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17481128 | 0.91 | CYP3A4 (0.82) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL28530363 | 0.90 | CYP3A4 (0.71) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL17481134 | 0.88 | CYP3A4 (0.78) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL13033264 | 0.88 | QPCT (0.71) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL17483163 | 0.88 | CYP3A4 (0.78) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL17483161 | 0.87 | QPCT (0.75) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL21858082 | 0.87 | QPCT (0.75) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL29419585 | 0.87 | CYP3A4 (0.76) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL2755863 | 0.86 | QPCT (0.73) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL13033285 | 0.85 | CYP3A4 (0.74) | CYP3A4CYP2D6TSHRCYP2C19QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026515-B | Attenuated influenza virus vectors for the prevention and/or treatment of infectious diseases and for the treatment of tumor diseases | 生物技术制药有限责任公司 | 2022-03-11 | — | — | CN | claimed |
| US-10392604-B2 | Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases | PHARMENTERPRISES BIOTECH Limited Liability Company (RU) | 2019-08-27 | — | — | US | claimed |
| EP-3382010-A2 | ATTENUATED INFLUENZA VECTORS FOR THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES AND FOR THE TREATMENT OF ONCOLOGICAL DISEASES | «PHARMENTERPRISES BIOTECH» LIMITED LIABILITY COMPANY (RU) | 2018-10-03 | — | — | EP | claimed |
| US-20180245052-A1 | ATTENUATED INFLUENZA VECTORS FOR THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES AND FOR THE TREATMENT OF ONCOLOGICAL DISEASES | PHARMENTERPRISES BIOTECH Limited Liability Company (RU) | 2018-08-30 | — | — | US | claimed |
| WO-2025095813-A1 | NOVEL COMPOUNDS | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТА-ИНТЕЛЛЕКТ" | 2025-05-08 | — | — | WO | disclosed |
| CN-112334464-B | Use of diamide derivatives of malonic acid for the treatment of allergic and other diseases in humans and animals | 瓦伦塔有限责任公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023224518-A1 | LIQUID PHARMACEUTICAL COMPOSITION CONTAINING N,N'-BIS[2-(1Н-IMIDAZOL-4-YL)ETHYL]MALONAMIDE FOR THE TREATMENT AND/OR PROPHYLAXIS OF RHINITIS | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТА-ИНТЕЛЛЕКТ" | 2023-11-23 | — | — | WO | disclosed |
| US-20230203016-A1 | DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVES | NEBOLSIN, VLADIMIR EVGENIEVICH (RU) | 2023-06-29 | — | — | US | disclosed |
| US-20230203016-A1 | DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVES | NEBOLSIN, VLADIMIR EVGENIEVICH (RU) | 2023-06-29 | — | — | US | disclosed |
| US-11571411-B2 | Use of a bisamide derivative of malonic acid for treating allergic and other diseases in humans and animals | PHARMENTERPRISES ALLERGY LLC (RU) | 2023-02-07 | — | — | US | disclosed |
| US-20220324843-A1 | DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVES | NEBOLSIN, VLADIMIR EVGENIEVICH (RU) | 2022-10-13 | — | — | US | disclosed |
| CN-108026515-B | Attenuated influenza virus vectors for the prevention and/or treatment of infectious diseases and for the treatment of tumor diseases | 生物技术制药有限责任公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-2985284-B1 | DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVES | TREAMID THERAPEUTICS GMBH (DE) | 2021-11-03 | — | — | EP | disclosed |
| US-20200087285-A1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2020-03-19 | — | — | US | disclosed |
| US-10392604-B2 | Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases | PHARMENTERPRISES BIOTECH Limited Liability Company (RU) | 2019-08-27 | — | — | US | disclosed |
| US-10392604-B2 | Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases | PHARMENTERPRISES BIOTECH Limited Liability Company (RU) | 2019-08-27 | — | — | US | disclosed |
| EP-3382010-A2 | ATTENUATED INFLUENZA VECTORS FOR THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES AND FOR THE TREATMENT OF ONCOLOGICAL DISEASES | «PHARMENTERPRISES BIOTECH» LIMITED LIABILITY COMPANY (RU) | 2018-10-03 | — | — | EP | disclosed |
| US-20180245052-A1 | ATTENUATED INFLUENZA VECTORS FOR THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES AND FOR THE TREATMENT OF ONCOLOGICAL DISEASES | PHARMENTERPRISES BIOTECH Limited Liability Company (RU) | 2018-08-30 | — | — | US | disclosed |
| US-20160031858-A1 | DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVES | TREAMID THERAPEUTICS GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
| US-20160031858-A1 | DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVES | TREAMID THERAPEUTICS GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203016-A1 | DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVES | GOT2, HADHA, ACAA2 | CYP3A4 761/4885CYP2D6 428/4885TSHR 2966/4885 |
| US-20180245052-A1 | ATTENUATED INFLUENZA VECTORS FOR THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES AND FOR THE TREATMENT OF ONCOLOGICAL DISEASES | HAVCR2, THEM6, TSG101 | CYP3A4 3253/4885CYP2D6 340/4885TSHR 3205/4885 |
| US-20160031858-A1 | DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVES | GOT2, HADHA, ACAA2 | CYP3A4 761/4885CYP2D6 428/4885TSHR 2966/4885 |
| US-10392604-B2 | Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases | HAVCR2, THEM6, TSG101 | CYP3A4 3253/4885CYP2D6 340/4885TSHR 3205/4885 |
| US-20220324843-A1 | DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVES | GOT2, HADHA, ACAA2 | CYP3A4 761/4885CYP2D6 428/4885TSHR 2966/4885 |
| US-20200087285-A1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | GLS, GLS2, QPCT | CYP3A4 3414/4885CYP2D6 2701/4885TSHR 3628/4885 |
| US-11571411-B2 | Use of a bisamide derivative of malonic acid for treating allergic and other diseases in humans and animals | HRH4, HRH2, HRH1 | CYP3A4 1327/4885CYP2D6 626/4885TSHR 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.